Where does Acceleron Pharma Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Acceleron Pharma Inc. ranks #3,055 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Acceleron Pharma Inc. hold?

Acceleron Pharma Inc. holds 124 US utility patents granted between 2015 and 2025, spanning 9 technology areas.

What is Acceleron Pharma Inc.'s Innovation Score?

Acceleron Pharma Inc. has an Innovation Score of 42.6 out of 100 (top 30% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Acceleron Pharma Inc. focus on?

Acceleron Pharma Inc.'s top technology area is C07K (Peptides) with 119 patents, ranking #58 of 3,615 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Acceleron Pharma Inc.'s patent grant rate increasing or decreasing?

Acceleron Pharma Inc.'s recent grant velocity is +37% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Acceleron Pharma Inc.'s patents?

Acceleron Pharma Inc.'s patents average 20.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Acceleron Pharma Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Acceleron Pharma Inc.

USPTO PatentsView assignee record - 124 granted patents across 9 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Acceleron ranks #3,055 of 49,997 tracked US assignees by granted-patent volume, with 124 patents across 9 technology areas.

#3,055
of 49,997 US assignees by volume: Top 30%
by Innovation Score (42.6/100): 20.0
avg claims per patent: +37%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3055 · US Corporation #3,055 · 124 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-MID 124 grants
TOP-DECILE #3,055/49,997
PHOTO-FINISH ArianeGroup SAS
CPC-NARROW C07K · 9 areas
INNOV-PAR 42.6/100
CLAIMS-DENSE 20.0 claims/avg
TYPE-USCORP US Corporation
VEL-UP +37% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: ArianeGroup SAS (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Acceleron’s 42.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 16.7 pts (39%) Velocity 3.3 pts (8%) Breadth 10.6 pts (25%) Claim depth 12.0 pts (28%)

Qualcomm Incorporated · highest

85
Acceleron Pharma · this assignee

43
Enel X North America · near

43
Nidec Copal · near

43
OLogN · near

43
Tekni-Plex · near

43
3D Lighting… · lowest

7

What this shows Acceleron's Innovation Score is 42.6/100 (top 30% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Acceleron?

Each dot is one of Acceleron’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Acceleron’s own 20.0 claims/patent is ABOVE the 15.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Acceleron vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Acceleron's grants concentrate

Acceleron Pharma Inc. is a focused PatentsView assignee: 9 CPC subclasses with 96% of grants classified under C07K (Peptides). Peak complete grant year is 2021 (27 grants) versus a trough of 5 in 2015. By volume, Acceleron sits between Université Laval and Bfly Operations, Inc..

Acceleron's three-year grant acceleration

From 2019–2021 to 2022–2024, Acceleron Pharma Inc. moved from 55 to 27 grants (0.49x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,712. See the growth leaderboard.

Université Laval

125
V-nova Internatio…

125
Wm Wrigley Jr

125
ASM Technology Si…

124
Arianegroup SAS

124
Avaya Management

124
Beijing Goldwind…

124
Bfly Operations

124
Acceleron Pharma ◀

124

What this shows Acceleron holds 124 patents at rank #3,056, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Acceleron

By rank, the assignees closest to #3,056 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Acceleron's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Acceleron, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Acceleron ranks #58 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (43 here).

Enel X North America, Inc. 43 OLogN Technologies AG 43 Tekni-Plex, Inc. 43 Nidec Copal Electronics Corporation 43

Similar claim depth

Nearest assignees by average claims per patent (20.0 here).

Wiz, Inc. 20.0 avg Sensor Electronic Technology, Inc. 20.0 avg iRobot Corporation 20.0 avg US Synthetic Corporation 20.0 avg

Acceleron's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 30% higher than 70% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Acceleron Pharma Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	4.0%
2016	10	8.1%
2017	7	5.6%
2018	12	9.7%
2019	15	12.1%
2020	13	10.5%
2021	27	21.8%
2022	10	8.1%
2023	6	4.8%
2024	11	8.9%
2025partial year	8	6.5%

Which technologies does Acceleron Pharma Inc. patent most?

C07K - Peptides 119

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 117

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 109

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 27

C12Y - Enzymes 25

Y02A - Technologies FOR Adaptation TO Climate Change 16

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 7

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 4

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Acceleron Pharma Inc.'s patent record in context - here's where to go next.

Acceleron Pharma Inc.'s lead technology class is C07K (Peptides), 96% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #3,055 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Acceleron Pharma Inc. against Université Laval, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.